Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹368 Cr
Revenue (TTM)
₹167 Cr
Net Profit (TTM)
₹9 Cr
ROE
3.2 %
ROCE
5.8 %
P/E Ratio
39
P/B Ratio
1.4
Industry P/E
43.12
EV/EBITDA
19
Div. Yield
0.4 %
Debt to Equity
0.2
Book Value
₹199.3
EPS
₹7.1
Face value
10
Shares outstanding
13,562,815
CFO
₹17.13 Cr
EBITDA
₹176.86 Cr
Net Profit
₹98.88 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Medicamen Biotech
| -25.5 | -16.7 | -31.3 | -34.8 | -23.9 | -- | -- |
|
BSE Healthcare
| -1.7 | -1.1 | -1.9 | 7.5 | 25.6 | 15.6 | 10.7 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Medicamen Biotech
| -27.8 | -13.3 | -27.4 | -6.4 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Medicamen Biotech
|
271.6 | 367.9 | 166.7 | 7.2 | 3.9 | 3.9 | 39 | 1.4 |
| 1,346.9 | 22,583.1 | 2,662.8 | 533.1 | 22.9 | 24.1 | 42.7 | 8.8 | |
| 672.0 | 26,925.4 | 3,626.9 | 315.0 | 15.0 | 13.3 | 89.5 | 11.6 | |
| 605.1 | 1,960.4 | 766.3 | 80.5 | 15.7 | 8.9 | 24.4 | 2.1 | |
| 1,867.9 | 9,674.7 | 1,566.5 | 169.5 | 14.8 | 12.7 | 57.5 | 6.6 | |
| 554.0 | 5,553.4 | 755.8 | 67.1 | -- | 13.8 | 82.8 | 5.7 | |
| 285.6 | 929.3 | 1,231.3 | 29.1 | -4.7 | 4 | 35.7 | 1.4 | |
| 263.9 | 1,360.9 | 294.1 | 32.4 | 17.4 | 15.1 | 40.9 | 5.7 | |
| 372.7 | 5,934.5 | 792.3 | 135.5 | 23.5 | 26.4 | 43.1 | 8.9 | |
| 938.2 | 9,082.5 | 768.1 | 159.9 | 29.2 | 19.3 | 57 | 10.0 |
No Review & Analysis are available.
Medicamen Biotech Limited researches, develops, manufactures, markets, sells, and distributes pharmaceutical formulations and APIs in India. The company offers a range of products, including tablets, such as non-beta lactam tablets; capsules... comprising beta and non-beta lactam capsules; liquid and dry syrups; and ointments and creams. It also provides oral solid and liquid products. The company's products are used in various therapeutic areas, such as gastrointestinal, pain management, anti-infectives, pediatrics, dermatology, gynecology and rheumatology, diabetology, cardiology, oncology, and the central nervous system. Medicamen Biotech Limited was incorporated in 1993 and is based in New Delhi, India. Read more
Incorporated
1993
Chairman
Rahul Bishnoi
Managing Director
--
Headquarters
New Delhi, Delhi
Website
Looking for more details about Medicamen Biotech Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
The share price of Medicamen Biotech Ltd is ₹271.55 (NSE) and ₹271.25 (BSE) as of 18-Mar-2026 IST. Medicamen Biotech Ltd has given a return of -23.95% in the last 3 years.
The P/E ratio of Medicamen Biotech Ltd is 39.04 times as on 18-Mar-2026, a 9 discount to its peers’ median range of 43.12 times.
The P/B ratio of Medicamen Biotech Ltd is 1.36 times as on 18-Mar-2026, a 82 discount to its peers’ median range of 7.40 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
93.43
|
2.97
|
|
2024
|
51.31
|
2.43
|
|
2023
|
56.31
|
4.51
|
|
2022
|
52.79
|
5.67
|
|
2021
|
53.78
|
5.17
|
The 52-week high and low of Medicamen Biotech Ltd are Rs 544.00 and Rs 263.25 as of 19-Mar-2026.
Medicamen Biotech Ltd has a market capitalisation of ₹ 368 Cr as on 18-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Medicamen Biotech Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹1.10
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.